Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

2010/04/20 by Tadashi Ishibashi, Tomoko Horisawa, Kumiko Tokuda +15 · 27 citations
Neuroscience · Biochemistry, Genetics and Molecular Biology · #Neuroscience and Neuropharmacology Research #Neurotransmitter Receptor Influence on Behavior #Pharmacological Receptor Mechanisms and Effects

paper · doi:10.1124/jpet.110.167346

Cited by

• International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function
• Antipsychotic [wikipedia]
• Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. [europepmc]
• Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. [europepmc]
• Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. [europepmc]
• 5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders. [europepmc]
• The serotonin receptor 7 and the structural plasticity of brain circuits. [europepmc]
• The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis. [europepmc]
• Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. [europepmc]
• In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. [europepmc]
• Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. [europepmc]
• Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. [europepmc]
• Clozapine as a Model for Antipsychotic Development. [europepmc]
• Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. [europepmc]
• Therapeutic Potential of Selectively Targeting the α 2C -Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective. [europepmc]
• Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. [europepmc]
• A History of the Pharmacological Treatment of Bipolar Disorder. [europepmc]
• Lurasidone inhibits NMDA receptor antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT 7 receptor blockade. [europepmc]
• Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus. [europepmc]
• Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects. [europepmc]
• Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. [europepmc]
• Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. [europepmc]
• International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. [europepmc]
• Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy. [europepmc]
• The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. [europepmc]
• Contrasting Typical and Atypical Antipsychotic Drugs. [europepmc]
• Structure, function and drug discovery of GPCR signaling. [europepmc]